MNPR

Monopar Therapeutics Inc. (MNPR) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on two primary areas: the development of ALXN1840 for Wilson disease (a rare genetic disorder) and a pipeline of radiopharmaceuticals based on the MNPR-101 antibody platform for oncology. The company has no approved products and has not generated any revenue to date.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by approximately $1.27 million compared to Q1 2025, driven primarily by a $1.84 million increase in Research and Development (R&D) expenses.
• R&D Expense Growth: R&D expenses rose to $3.49 million from $1.64 million, attributed to increased contractor/consulting fees ($826k increase) and personnel expenses ($800k increase).
• Higher Interest Income: Interest income more than doubled to $1.33 million, reflecting higher cash balances following the September 2025 capital raise and prevailing interest rates on U.S. Treasury securities and commercial paper.
• Cash Flow: Net cash used in operating activities decreased to $3.47 million (from $5.66 million in Q1 2025), largely because a $3 million upfront payment for the ALXN1840 license was made in Q1 2025 but not repeated in Q1 2026.
• Investing Activity: Net cash used in investing activities increased significantly to $5.58 million due to the deployment of capital from the September 2025 offering into short-term investments.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management estimates current cash and investments ($137.5 million) are sufficient to fund operations through December 31, 2027. No substantial doubt regarding going concern status exists as of the filing date.
• ALXN1840 (Wilson Disease): The company expects to submit a New Drug Application (NDA) in mid-2026. Recent data presented at the AAN (April 2026) showed durable neurologic benefits. However, the program was previously terminated by Alexion (AstraZeneca) due to Phase 2 mechanistic trial results; Monopar is proceeding based on Phase 3 efficacy data and long-term safety profiles.
• Radiopharmaceutical Pipeline:
  • MNPR-101-Zr: Phase 1 imaging trial active; FDA Expanded Access Program (EAP) authorized.
  • MNPR-101-Lu: Phase 1a therapeutic trial active; FDA IND clearance received in September 2025.
  • MNPR-101-Ac: Late preclinical stage.
• Key Risks:
  • Regulatory Uncertainty: FDA may require additional studies for ALXN1840 approval despite Phase 3 success, given Alexion's prior termination of the program.
  • Capital Requirements: Future funding is required for commercialization if approved, and for advancing the radiopharmaceutical pipeline. Additional equity raises may dilute shareholders.
  • Supply Chain: Reliance on third parties for radioisotope supply (e.g., Actinium-225) and manufacturing.
  • Geopolitical Factors: Potential impacts of global conflicts on supply chains and costs.

Investor Verification Checklist

• Verify the specific FDA feedback received regarding the ALXN1840 NDA submission timeline and any requested additional data.
• Confirm the status of the Expanded Access Program (EAP) for MNPR-101-Zr and patient enrollment numbers.
• Review the terms of the Alexion license agreement regarding milestone payments (up to $94 million) and royalty rates (10-20%) to understand future cash outflow obligations.
• Monitor the company's cash burn rate relative to the stated runway through end of 2027, particularly as R&D expenses increase.
• Assess the availability and cost of Actinium-225 supply under the NorthStar agreement for the MNPR-101-Ac program.